Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density - Staff

Novo Nordisk Foundation
Center for Protein Research

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Research output: Contribution to journal › Journal article › Research › peer-review

Documents

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Final published version, 201 KB, PDF document

Robert Eriksson
Brian V. Broberg
Pelle L. Ishoy
Nikolaj Bak
Ulrik B. Andersen
Niklas R. Jorgensen
Knop, Filip Krag
Ebdrup, Bjørn

Original language	English
Article number	781
Journal	Frontiers in Psychiatry
Volume	9
Number of pages	7
ISSN	1664-0640
DOIs	https://doi.org/10.3389/fpsyt.2018.00781
Publication status	Published - 2019

Research areas

exenatide, procollagen type I N-terminal propeptide (PINP), C-terminal cross-linking telopeptide of type I collagen (CTX), bone mineral density, randomized controlled trial

Number of downloads are based on statistics from Google Scholar and www.ku.dk

No data available

ID: 213322322